The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biomedical CRISPR Gene Editing Market Research Report 2025

Global Biomedical CRISPR Gene Editing Market Research Report 2025

Publishing Date : Apr, 2025

License Type :
 

Report Code : 2008449

No of Pages : 97

Ask Your Query
Synopsis
The global market for Biomedical CRISPR Gene Editing was valued at US$ 3500 million in the year 2024 and is projected to reach a revised size of US$ 7737 million by 2031, growing at a CAGR of 12.0% during the forecast period.
CRISPR gene editing technology is a gene editing tool based on the natural immune system of bacteria. It achieves precise cutting, insertion, or modification of specific DNA sequences by binding Cas proteins (such as Cas9, Cas12a, Cas3, Cas13, etc.) with guide RNA (gRNA). In the biomedical field, CRISPR gene editing is widely used in gene therapy, disease diagnosis, drug development, regenerative medicine, and other fields.
In recent years, the market size of biomedical CRISPR gene editing has been continuously growing. The main driving factors include the increasing demand for cancer treatment, commercialization of gene therapy, advances in CRISPR gene editing technology, and policy support from governments around the world. From a regional distribution perspective, North America holds the largest share of the global market, while the Asia Pacific region has the fastest market growth, especially in China. The European region continues to grow under strict regulation, especially in Germany and the UK, with a focus on cancer and regenerative medicine. The main participating companies in the market include international companies such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, as well as domestic companies such as GemPharmatech and Shanghai Model Organisms. In the biomedical field, gene therapy is the main application scenario of CRISPR gene editing. The main challenges currently facing the industry include technological bottlenecks, ethical and regulatory issues. Off target effects, low delivery system efficiency, and differences in relevant policies among countries have to some extent limited the application of CRISPR gene editing. Meanwhile, some emerging technological directions such as base editing and epigenome editing have also provided new research entry points for the industry. In short, the application of CRISPR gene editing in the biomedical field is rapidly moving from the laboratory to clinical practice, and the market size is continuously expanding driven by treatment demand and technological innovation. In the future, it is necessary to break through technological limitations and balance ethical regulation to unleash greater commercial value.
This report aims to provide a comprehensive presentation of the global market for Biomedical CRISPR Gene Editing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biomedical CRISPR Gene Editing.
The Biomedical CRISPR Gene Editing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biomedical CRISPR Gene Editing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biomedical CRISPR Gene Editing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Caribou Biosciences
Cellectis
Regeneron Pharmaceuticals
Beam Therapeutics
Sangamo Therapeutics
Invitae
Thermo Fisher Scientific
Merck
GemPharmatech
Shanghai Model Organisms
Vazyme Biotech
Biocytogen
Genemagic Bioscience
HuidaGene
BRL Medicine
ReforGene Medicine
Segment by Type
CRISPR-Cas9
CRISPR-Cas12a
CRISPR-Cas3
CRISPR-Cas13
Prime Editing
Others
Segment by Application
Gene Therapy
Disease Diagnosis
Drug Development
Regenerative Medicine
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biomedical CRISPR Gene Editing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biomedical CRISPR Gene Editing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 CRISPR-Cas9
1.2.3 CRISPR-Cas12a
1.2.4 CRISPR-Cas3
1.2.5 CRISPR-Cas13
1.2.6 Prime Editing
1.2.7 Others
1.3 Market by Application
1.3.1 Global Biomedical CRISPR Gene Editing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Gene Therapy
1.3.3 Disease Diagnosis
1.3.4 Drug Development
1.3.5 Regenerative Medicine
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biomedical CRISPR Gene Editing Market Perspective (2020-2031)
2.2 Global Biomedical CRISPR Gene Editing Growth Trends by Region
2.2.1 Global Biomedical CRISPR Gene Editing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Biomedical CRISPR Gene Editing Historic Market Size by Region (2020-2025)
2.2.3 Biomedical CRISPR Gene Editing Forecasted Market Size by Region (2026-2031)
2.3 Biomedical CRISPR Gene Editing Market Dynamics
2.3.1 Biomedical CRISPR Gene Editing Industry Trends
2.3.2 Biomedical CRISPR Gene Editing Market Drivers
2.3.3 Biomedical CRISPR Gene Editing Market Challenges
2.3.4 Biomedical CRISPR Gene Editing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biomedical CRISPR Gene Editing Players by Revenue
3.1.1 Global Top Biomedical CRISPR Gene Editing Players by Revenue (2020-2025)
3.1.2 Global Biomedical CRISPR Gene Editing Revenue Market Share by Players (2020-2025)
3.2 Global Top Biomedical CRISPR Gene Editing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biomedical CRISPR Gene Editing Revenue
3.4 Global Biomedical CRISPR Gene Editing Market Concentration Ratio
3.4.1 Global Biomedical CRISPR Gene Editing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biomedical CRISPR Gene Editing Revenue in 2024
3.5 Global Key Players of Biomedical CRISPR Gene Editing Head office and Area Served
3.6 Global Key Players of Biomedical CRISPR Gene Editing, Product and Application
3.7 Global Key Players of Biomedical CRISPR Gene Editing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biomedical CRISPR Gene Editing Breakdown Data by Type
4.1 Global Biomedical CRISPR Gene Editing Historic Market Size by Type (2020-2025)
4.2 Global Biomedical CRISPR Gene Editing Forecasted Market Size by Type (2026-2031)
5 Biomedical CRISPR Gene Editing Breakdown Data by Application
5.1 Global Biomedical CRISPR Gene Editing Historic Market Size by Application (2020-2025)
5.2 Global Biomedical CRISPR Gene Editing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Biomedical CRISPR Gene Editing Market Size (2020-2031)
6.2 North America Biomedical CRISPR Gene Editing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Biomedical CRISPR Gene Editing Market Size by Country (2020-2025)
6.4 North America Biomedical CRISPR Gene Editing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biomedical CRISPR Gene Editing Market Size (2020-2031)
7.2 Europe Biomedical CRISPR Gene Editing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Biomedical CRISPR Gene Editing Market Size by Country (2020-2025)
7.4 Europe Biomedical CRISPR Gene Editing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biomedical CRISPR Gene Editing Market Size (2020-2031)
8.2 Asia-Pacific Biomedical CRISPR Gene Editing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Biomedical CRISPR Gene Editing Market Size by Region (2020-2025)
8.4 Asia-Pacific Biomedical CRISPR Gene Editing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biomedical CRISPR Gene Editing Market Size (2020-2031)
9.2 Latin America Biomedical CRISPR Gene Editing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Biomedical CRISPR Gene Editing Market Size by Country (2020-2025)
9.4 Latin America Biomedical CRISPR Gene Editing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biomedical CRISPR Gene Editing Market Size (2020-2031)
10.2 Middle East & Africa Biomedical CRISPR Gene Editing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Biomedical CRISPR Gene Editing Market Size by Country (2020-2025)
10.4 Middle East & Africa Biomedical CRISPR Gene Editing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CRISPR Therapeutics
11.1.1 CRISPR Therapeutics Company Details
11.1.2 CRISPR Therapeutics Business Overview
11.1.3 CRISPR Therapeutics Biomedical CRISPR Gene Editing Introduction
11.1.4 CRISPR Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.1.5 CRISPR Therapeutics Recent Development
11.2 Editas Medicine
11.2.1 Editas Medicine Company Details
11.2.2 Editas Medicine Business Overview
11.2.3 Editas Medicine Biomedical CRISPR Gene Editing Introduction
11.2.4 Editas Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.2.5 Editas Medicine Recent Development
11.3 Intellia Therapeutics
11.3.1 Intellia Therapeutics Company Details
11.3.2 Intellia Therapeutics Business Overview
11.3.3 Intellia Therapeutics Biomedical CRISPR Gene Editing Introduction
11.3.4 Intellia Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.3.5 Intellia Therapeutics Recent Development
11.4 Caribou Biosciences
11.4.1 Caribou Biosciences Company Details
11.4.2 Caribou Biosciences Business Overview
11.4.3 Caribou Biosciences Biomedical CRISPR Gene Editing Introduction
11.4.4 Caribou Biosciences Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.4.5 Caribou Biosciences Recent Development
11.5 Cellectis
11.5.1 Cellectis Company Details
11.5.2 Cellectis Business Overview
11.5.3 Cellectis Biomedical CRISPR Gene Editing Introduction
11.5.4 Cellectis Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.5.5 Cellectis Recent Development
11.6 Regeneron Pharmaceuticals
11.6.1 Regeneron Pharmaceuticals Company Details
11.6.2 Regeneron Pharmaceuticals Business Overview
11.6.3 Regeneron Pharmaceuticals Biomedical CRISPR Gene Editing Introduction
11.6.4 Regeneron Pharmaceuticals Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.6.5 Regeneron Pharmaceuticals Recent Development
11.7 Beam Therapeutics
11.7.1 Beam Therapeutics Company Details
11.7.2 Beam Therapeutics Business Overview
11.7.3 Beam Therapeutics Biomedical CRISPR Gene Editing Introduction
11.7.4 Beam Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.7.5 Beam Therapeutics Recent Development
11.8 Sangamo Therapeutics
11.8.1 Sangamo Therapeutics Company Details
11.8.2 Sangamo Therapeutics Business Overview
11.8.3 Sangamo Therapeutics Biomedical CRISPR Gene Editing Introduction
11.8.4 Sangamo Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.8.5 Sangamo Therapeutics Recent Development
11.9 Invitae
11.9.1 Invitae Company Details
11.9.2 Invitae Business Overview
11.9.3 Invitae Biomedical CRISPR Gene Editing Introduction
11.9.4 Invitae Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.9.5 Invitae Recent Development
11.10 Thermo Fisher Scientific
11.10.1 Thermo Fisher Scientific Company Details
11.10.2 Thermo Fisher Scientific Business Overview
11.10.3 Thermo Fisher Scientific Biomedical CRISPR Gene Editing Introduction
11.10.4 Thermo Fisher Scientific Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.10.5 Thermo Fisher Scientific Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Biomedical CRISPR Gene Editing Introduction
11.11.4 Merck Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.11.5 Merck Recent Development
11.12 GemPharmatech
11.12.1 GemPharmatech Company Details
11.12.2 GemPharmatech Business Overview
11.12.3 GemPharmatech Biomedical CRISPR Gene Editing Introduction
11.12.4 GemPharmatech Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.12.5 GemPharmatech Recent Development
11.13 Shanghai Model Organisms
11.13.1 Shanghai Model Organisms Company Details
11.13.2 Shanghai Model Organisms Business Overview
11.13.3 Shanghai Model Organisms Biomedical CRISPR Gene Editing Introduction
11.13.4 Shanghai Model Organisms Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.13.5 Shanghai Model Organisms Recent Development
11.14 Vazyme Biotech
11.14.1 Vazyme Biotech Company Details
11.14.2 Vazyme Biotech Business Overview
11.14.3 Vazyme Biotech Biomedical CRISPR Gene Editing Introduction
11.14.4 Vazyme Biotech Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.14.5 Vazyme Biotech Recent Development
11.15 Biocytogen
11.15.1 Biocytogen Company Details
11.15.2 Biocytogen Business Overview
11.15.3 Biocytogen Biomedical CRISPR Gene Editing Introduction
11.15.4 Biocytogen Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.15.5 Biocytogen Recent Development
11.16 Genemagic Bioscience
11.16.1 Genemagic Bioscience Company Details
11.16.2 Genemagic Bioscience Business Overview
11.16.3 Genemagic Bioscience Biomedical CRISPR Gene Editing Introduction
11.16.4 Genemagic Bioscience Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.16.5 Genemagic Bioscience Recent Development
11.17 HuidaGene
11.17.1 HuidaGene Company Details
11.17.2 HuidaGene Business Overview
11.17.3 HuidaGene Biomedical CRISPR Gene Editing Introduction
11.17.4 HuidaGene Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.17.5 HuidaGene Recent Development
11.18 BRL Medicine
11.18.1 BRL Medicine Company Details
11.18.2 BRL Medicine Business Overview
11.18.3 BRL Medicine Biomedical CRISPR Gene Editing Introduction
11.18.4 BRL Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.18.5 BRL Medicine Recent Development
11.19 ReforGene Medicine
11.19.1 ReforGene Medicine Company Details
11.19.2 ReforGene Medicine Business Overview
11.19.3 ReforGene Medicine Biomedical CRISPR Gene Editing Introduction
11.19.4 ReforGene Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025)
11.19.5 ReforGene Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
List of Tables
Table 1. Global Biomedical CRISPR Gene Editing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of CRISPR-Cas9
Table 3. Key Players of CRISPR-Cas12a
Table 4. Key Players of CRISPR-Cas3
Table 5. Key Players of CRISPR-Cas13
Table 6. Key Players of Prime Editing
Table 7. Key Players of Others
Table 8. Global Biomedical CRISPR Gene Editing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Biomedical CRISPR Gene Editing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Biomedical CRISPR Gene Editing Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Biomedical CRISPR Gene Editing Market Share by Region (2020-2025)
Table 12. Global Biomedical CRISPR Gene Editing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Biomedical CRISPR Gene Editing Market Share by Region (2026-2031)
Table 14. Biomedical CRISPR Gene Editing Market Trends
Table 15. Biomedical CRISPR Gene Editing Market Drivers
Table 16. Biomedical CRISPR Gene Editing Market Challenges
Table 17. Biomedical CRISPR Gene Editing Market Restraints
Table 18. Global Biomedical CRISPR Gene Editing Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Biomedical CRISPR Gene Editing Market Share by Players (2020-2025)
Table 20. Global Top Biomedical CRISPR Gene Editing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biomedical CRISPR Gene Editing as of 2024)
Table 21. Ranking of Global Top Biomedical CRISPR Gene Editing Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Biomedical CRISPR Gene Editing Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Biomedical CRISPR Gene Editing, Headquarters and Area Served
Table 24. Global Key Players of Biomedical CRISPR Gene Editing, Product and Application
Table 25. Global Key Players of Biomedical CRISPR Gene Editing, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Biomedical CRISPR Gene Editing Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Biomedical CRISPR Gene Editing Revenue Market Share by Type (2020-2025)
Table 29. Global Biomedical CRISPR Gene Editing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Biomedical CRISPR Gene Editing Revenue Market Share by Type (2026-2031)
Table 31. Global Biomedical CRISPR Gene Editing Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Biomedical CRISPR Gene Editing Revenue Market Share by Application (2020-2025)
Table 33. Global Biomedical CRISPR Gene Editing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Biomedical CRISPR Gene Editing Revenue Market Share by Application (2026-2031)
Table 35. North America Biomedical CRISPR Gene Editing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Biomedical CRISPR Gene Editing Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Biomedical CRISPR Gene Editing Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Biomedical CRISPR Gene Editing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Biomedical CRISPR Gene Editing Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Biomedical CRISPR Gene Editing Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Biomedical CRISPR Gene Editing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Biomedical CRISPR Gene Editing Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Biomedical CRISPR Gene Editing Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Biomedical CRISPR Gene Editing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Biomedical CRISPR Gene Editing Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Biomedical CRISPR Gene Editing Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Biomedical CRISPR Gene Editing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Biomedical CRISPR Gene Editing Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Biomedical CRISPR Gene Editing Market Size by Country (2026-2031) & (US$ Million)
Table 50. CRISPR Therapeutics Company Details
Table 51. CRISPR Therapeutics Business Overview
Table 52. CRISPR Therapeutics Biomedical CRISPR Gene Editing Product
Table 53. CRISPR Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 54. CRISPR Therapeutics Recent Development
Table 55. Editas Medicine Company Details
Table 56. Editas Medicine Business Overview
Table 57. Editas Medicine Biomedical CRISPR Gene Editing Product
Table 58. Editas Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 59. Editas Medicine Recent Development
Table 60. Intellia Therapeutics Company Details
Table 61. Intellia Therapeutics Business Overview
Table 62. Intellia Therapeutics Biomedical CRISPR Gene Editing Product
Table 63. Intellia Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 64. Intellia Therapeutics Recent Development
Table 65. Caribou Biosciences Company Details
Table 66. Caribou Biosciences Business Overview
Table 67. Caribou Biosciences Biomedical CRISPR Gene Editing Product
Table 68. Caribou Biosciences Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 69. Caribou Biosciences Recent Development
Table 70. Cellectis Company Details
Table 71. Cellectis Business Overview
Table 72. Cellectis Biomedical CRISPR Gene Editing Product
Table 73. Cellectis Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 74. Cellectis Recent Development
Table 75. Regeneron Pharmaceuticals Company Details
Table 76. Regeneron Pharmaceuticals Business Overview
Table 77. Regeneron Pharmaceuticals Biomedical CRISPR Gene Editing Product
Table 78. Regeneron Pharmaceuticals Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 79. Regeneron Pharmaceuticals Recent Development
Table 80. Beam Therapeutics Company Details
Table 81. Beam Therapeutics Business Overview
Table 82. Beam Therapeutics Biomedical CRISPR Gene Editing Product
Table 83. Beam Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 84. Beam Therapeutics Recent Development
Table 85. Sangamo Therapeutics Company Details
Table 86. Sangamo Therapeutics Business Overview
Table 87. Sangamo Therapeutics Biomedical CRISPR Gene Editing Product
Table 88. Sangamo Therapeutics Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 89. Sangamo Therapeutics Recent Development
Table 90. Invitae Company Details
Table 91. Invitae Business Overview
Table 92. Invitae Biomedical CRISPR Gene Editing Product
Table 93. Invitae Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 94. Invitae Recent Development
Table 95. Thermo Fisher Scientific Company Details
Table 96. Thermo Fisher Scientific Business Overview
Table 97. Thermo Fisher Scientific Biomedical CRISPR Gene Editing Product
Table 98. Thermo Fisher Scientific Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 99. Thermo Fisher Scientific Recent Development
Table 100. Merck Company Details
Table 101. Merck Business Overview
Table 102. Merck Biomedical CRISPR Gene Editing Product
Table 103. Merck Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 104. Merck Recent Development
Table 105. GemPharmatech Company Details
Table 106. GemPharmatech Business Overview
Table 107. GemPharmatech Biomedical CRISPR Gene Editing Product
Table 108. GemPharmatech Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 109. GemPharmatech Recent Development
Table 110. Shanghai Model Organisms Company Details
Table 111. Shanghai Model Organisms Business Overview
Table 112. Shanghai Model Organisms Biomedical CRISPR Gene Editing Product
Table 113. Shanghai Model Organisms Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 114. Shanghai Model Organisms Recent Development
Table 115. Vazyme Biotech Company Details
Table 116. Vazyme Biotech Business Overview
Table 117. Vazyme Biotech Biomedical CRISPR Gene Editing Product
Table 118. Vazyme Biotech Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 119. Vazyme Biotech Recent Development
Table 120. Biocytogen Company Details
Table 121. Biocytogen Business Overview
Table 122. Biocytogen Biomedical CRISPR Gene Editing Product
Table 123. Biocytogen Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 124. Biocytogen Recent Development
Table 125. Genemagic Bioscience Company Details
Table 126. Genemagic Bioscience Business Overview
Table 127. Genemagic Bioscience Biomedical CRISPR Gene Editing Product
Table 128. Genemagic Bioscience Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 129. Genemagic Bioscience Recent Development
Table 130. HuidaGene Company Details
Table 131. HuidaGene Business Overview
Table 132. HuidaGene Biomedical CRISPR Gene Editing Product
Table 133. HuidaGene Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 134. HuidaGene Recent Development
Table 135. BRL Medicine Company Details
Table 136. BRL Medicine Business Overview
Table 137. BRL Medicine Biomedical CRISPR Gene Editing Product
Table 138. BRL Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 139. BRL Medicine Recent Development
Table 140. ReforGene Medicine Company Details
Table 141. ReforGene Medicine Business Overview
Table 142. ReforGene Medicine Biomedical CRISPR Gene Editing Product
Table 143. ReforGene Medicine Revenue in Biomedical CRISPR Gene Editing Business (2020-2025) & (US$ Million)
Table 144. ReforGene Medicine Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
Table 148. Authors List of This Report


List of Figures
Figure 1. Biomedical CRISPR Gene Editing Picture
Figure 2. Global Biomedical CRISPR Gene Editing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Biomedical CRISPR Gene Editing Market Share by Type: 2024 VS 2031
Figure 4. CRISPR-Cas9 Features
Figure 5. CRISPR-Cas12a Features
Figure 6. CRISPR-Cas3 Features
Figure 7. CRISPR-Cas13 Features
Figure 8. Prime Editing Features
Figure 9. Others Features
Figure 10. Global Biomedical CRISPR Gene Editing Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Biomedical CRISPR Gene Editing Market Share by Application: 2024 VS 2031
Figure 12. Gene Therapy Case Studies
Figure 13. Disease Diagnosis Case Studies
Figure 14. Drug Development Case Studies
Figure 15. Regenerative Medicine Case Studies
Figure 16. Others Case Studies
Figure 17. Biomedical CRISPR Gene Editing Report Years Considered
Figure 18. Global Biomedical CRISPR Gene Editing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Biomedical CRISPR Gene Editing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Biomedical CRISPR Gene Editing Market Share by Region: 2024 VS 2031
Figure 21. Global Biomedical CRISPR Gene Editing Market Share by Players in 2024
Figure 22. Global Biomedical CRISPR Gene Editing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. The Top 10 and 5 Players Market Share by Biomedical CRISPR Gene Editing Revenue in 2024
Figure 24. North America Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Biomedical CRISPR Gene Editing Market Share by Country (2020-2031)
Figure 26. United States Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Biomedical CRISPR Gene Editing Market Share by Country (2020-2031)
Figure 30. Germany Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Biomedical CRISPR Gene Editing Market Share by Region (2020-2031)
Figure 38. China Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Biomedical CRISPR Gene Editing Market Share by Country (2020-2031)
Figure 46. Mexico Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Biomedical CRISPR Gene Editing Market Share by Country (2020-2031)
Figure 50. Turkey Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Biomedical CRISPR Gene Editing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. CRISPR Therapeutics Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 54. Editas Medicine Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 55. Intellia Therapeutics Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 56. Caribou Biosciences Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 57. Cellectis Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 58. Regeneron Pharmaceuticals Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 59. Beam Therapeutics Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 60. Sangamo Therapeutics Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 61. Invitae Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 62. Thermo Fisher Scientific Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 63. Merck Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 64. GemPharmatech Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 65. Shanghai Model Organisms Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 66. Vazyme Biotech Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 67. Biocytogen Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 68. Genemagic Bioscience Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 69. HuidaGene Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 70. BRL Medicine Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 71. ReforGene Medicine Revenue Growth Rate in Biomedical CRISPR Gene Editing Business (2020-2025)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock